FMP
IntelGenx Technologies Corp.
IGXT
PNK
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
0.17 USD
0 (0%)
IGXT Financial Statements
Year
2023
2022
2021
2020
Current Assets
3.44M
3.79M
11.44M
4.3M
Cash & Short Term Investments
2.28M
2.53M
9.95M
2.24M
Cash And Cash Equivalents
2.28M
1.21M
3.94M
1.21M
Short Term Investments
0
1.32M
6M
1.04M
Net Receivables
790k
868k
1.12M
1.25M
Inventory
71k
62k
62k
244k
Other Current Assets
298k
331k
310k
569k
Non-Current Assets
4.84M
5.4M
6.47M
6.81M
Property, Plant & Equipment
4.59M
5.16M
6.22M
6.56M
Goodwill And Intangible Assets
0
0
0
0
Goodwill
0
0
0
0
Intangible Assets
0
0
0
0
Long Term Investments
0
0
0
0
Tax Assets
0
0
79k
0
Other Non-Current Assets
250k
245k
173k
252k
Other Assets
0
0
0
0
Total Assets
8.28M
9.19M
17.91M
11.12M
Current Liabilities
8.42M
2.37M
7.02M
4.37M
Accounts Payable
2.66M
1.52M
2.3M
1.99M
Short Term Debt
3.4M
544k
4.53M
2.21M
Tax Payables
0
0
0
0
Deferred Revenue
1.12M
-189k
189k
166k
Other Current Liabilities
1.25M
307k
0
0
Total Current Liabilities
8.42M
2.37M
7.02M
4.37M
Total Non-Current Liabilities
12.11M
10.24M
7.01M
7.7M
Long-Term Debt
12.11M
10.24M
7.66M
7.7M
Deferred Revenue
0
-189k
-79k
0
Deferred Taxes Liabilities
0
0
79k
0
Other Non Current liabilities
0
0
-726k
0
Total Liabilities
20.53M
12.61M
14.03M
12.07M
Other Liabilities
0
0
0
0
Stockholders Equity
-12.25M
-3.42M
3.87M
-953k
Common Stock
1k
1k
1k
1k
Retained Earnings
-78.46M
-68.53M
-57.86M
-48.55M
Accumulated Other Comprehensive Income/Loss
-2.45M
-2.23M
-1.37M
-856k
Other Shareholders Equity
-
-
-
-
Retained Earning Schedule
Year
2023
2022
2021
2020
Retained Earnings (Previous Year)
-68.53M
-57.86M
-48.55M
-41.51M
Net Income
-9.93M
-11.97M
-9.31M
-8.25M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-78.46M
-68.53M
-57.86M
-48.55M
Other Distributions
-9.93M
-10.67M
-9.31M
-7.04M
PPE Schedule
Year
2023
2022
2021
2020
Gross PPE
4.59M
5.16M
6.22M
6.56M
Annual Depreciation
766k
777k
791k
734k
Capital Expenditure
-180k
-271k
-108k
-120k
Net PPE
4M
4.65M
5.53M
5.95M
Intangible and Goodwill Schedule
Year
2023
2022
2021
2020
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
